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Abbreviations 
 
HCC: Hepatocellular carcinoma 
HBV: hepatitis B virus 
HCV: hepatitis C virus 
AFP: alpha-fetoprotein 
PIVKA-II: Protein induced by vitamin K absence or antagonist-II 
DCP: des-gamma-carboxy prothrombin 
AFP-L3: AFP fraction with affinity to the Lens culinaris agglutinin 
Glu: glutamic acid residues 
Gla: γ-carboxy glutamic acid 
GANP: germinal center-associated nuclear protein 
RST: rapid serum tube including thrombin 
GPC: gel permeation chromatography 
RLUs: relative light units 
SST: serum separator tube 
IC50: half maximal Inhibitory Concentrations 
%CV: percentage coefficient of variation 
LoB: limit of blank 
LoD: limit of detection 
LoQ: limit of quantitation 
CLSI: Clinical and Laboratory Standards Institute 
SD: standard deviation 
BD: Becton, Dickinson and Company 
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aa: amino acid 
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Chapter I: 
Preface 
 
Introduction 
Liver cancer is the second most common cause of death from cancer 
worldwide and is given very poor prognosis [1].  Hepatocellular 
carcinoma (HCC) is the major histologic type among primary liver cancers 
occurring worldwide, accounting for 70% to 85% of total burden [2].  
Chronic infection by either hepatitis B virus (HBV) or hepatitis C virus 
(HCV) is a major risk factor for HCC.  Approximately 80% of HCC is 
estimated to be attributable to HBV or HCV worldwide [3].  Carcinogenic 
risk of HBV carriers is 223-fold that of non-carriers [4].  Infection by 
HCV is the most common predisposing factor in some developed countries, 
including Japan [5]. 
One of the reasons for the high fatality rate of HCC is the difficulty of 
detection for HCC in early stage since it is an asymptomatic disease; 
therefore many patients are not treated in the early stages.  Early detection 
of HCC by surveillance in high risk groups is an appropriate way to 
improve the survival rate in patients with HCC [6-11].  HCC can be 
treated by resection, liver transplantation, or local ablation with 
radiofrequency for patients diagnosed at an early stage [12].  However, 
although alpha-fetoprotein (AFP) is the most commonly used tumor marker 
for HCC, its clinical diagnostic accuracy is unsatisfactory due to low 
sensitivity and specificity [13].  Therefore, there is an urgent need for 
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developing better HCC-specific biomarkers.  Several serological 
biomarkers have been suggested as other potential biomarkers for early 
detection of HCC. 
 
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a 
tumor marker for HCC 
PIVKA-II, also known as des-gamma-carboxy prothrombin (DCP), is a 
useful marker for the diagnosis of HCC [13, 14].  PIVKA-II level is not 
correlated with the levels of AFP or AFP fraction with affinity to the Lens 
culinaris agglutinin (AFP-L3), which are other representative biomarkers 
for HCC.  Therefore, PIVKA-II can be used along with AFP or AFP-L3 
as a complementary biomarker for HCC.  Thus, the combination of two 
markers enhances the sensitivity of diagnosis of HCC, but minimizes the 
decrease in specificity [15-18].  The Japan Society of Hepatology 
recommends measurement of two or more tumor markers for the diagnosis 
of HCC [19].  Also, the measurement of AFP, AFP-L3 and PIVKA-II is 
covered by the National Health Insurance in Japan.  PIVKA-II has been 
used as an aid for diagnosis of HCC and monitoring of high risk patients 
(HCV infections, HBV infections, and hepatitis/cirrhosis) for development 
of HCC for more than 20 years in Japan [19]. 
Many studies showed serum PIVKA-II levels are related to tumor size, 
vascular invasion, intrahepatic metastasis and frequency of recurrence after 
treatment [20-24].  PIVKA-II secreted from HCC cells strongly promotes 
HCC growth and metastasis through the mechanisms of autocrine 
8 
 
stimulation and paracrine interaction factor between HCC and human 
vascular endotherial cells [25, 26].  The autocrine secretion actives c-Met 
phosphorylation and affects self-proliferation of HCC through the 
c-Met-JAK-STAT3 pathway [27].  Also, PIVKA-II stimulates HCC 
invasion through activation of the ERK1/2 MAPK pathway [27].  The 
paracrine secretion stimulates proliferation and migration of vascular 
endothelial cells via release of VEGF, TGF-α, and bFGF and activation of 
the KDR-PLC-γ-MAPK pathway [27].  Recently, the clinical report 
showed enhanced antitumor action of sorafenib, which is a 
molecular-targeting anti-cancer agent that inhibits the serine-threonine 
kinase Raf and the tyrosine kinase activity if VEGF receptors, by vitamin K. 
It is suggest that vitamin K may have the synergistic effect by suppressing 
production of PIVKA-II [28]. 
Prothrombin, a blood coagulation protein synthesized in the liver, is 
converted to an active form after the 10 glutamic acid residues (Glu) in the 
γ-carboxy glutamic acid (Gla) domain at positions 6, 7, 14, 16, 19, 20, 25, 
26, 29 and 32 are γ-carboxylated to Gla by vitamin-K dependent 
γ-glutamyl carboxylase.  In patients with HCC, γ-carboxylation of 
prothrombin is impaired so that PIVKA-II is formed instead of 
prothrombin [29].  The production of normal prothrombin and PIVKA-II 
in hepatic cells is shown in Figure 1.  Liebman et al. [16] first reported 
that the serum PIVKA-II concentration was significantly higher in patients 
with HCC by radioimmunoassay using a polyclonal antibody.  They 
purified PIVKA-II from ascites fluid of patients with HCC and analyzed its 
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Gla content [30].  Then, Motohara et al. [31, 32] made the MU-3 
monoclonal antibody against PIVKA-II and established an assay system 
with higher sensitivity.  Clinical studies have demonstrated that the assay 
system using MU-3 antibody shows high sensitivity and specificity to 
PIVKA-II in patients with HCC [33].  Sugo et al. [34] reported that the 
reactivity of MU-3 antibody increased when the number of Gla was less 
than five per molecule.  Furthermore, Naraki et al. [35] described the 
epitope of PIVKA-II reacting to MU-3 antibody.  The epitope of MU-3 
antibody was located within the amino acid residues 17–27 in the Gla 
domain.  They reported that MU-3 antibody reacted to PIVKA-II with less 
than four Gla and PIVKA-II variants preferentially synthesized in HCC 
patients have less than four Gla whereas PIVKA-II variants in benign liver 
diseases have more than five Gla [35].  The MU-3 antibody is used for the 
almost diagnostic reagents to achieve the high sensitivity and specificity.  
It was necessary that a new monoclonal antibody against PIVKA-II is 
established instead of MU-3 antibody to distribute the PIVKA-II diagnostic 
reagent in worldwide.  Therefore, the establishment of the new 
monoclonal antibody against PIVKA-II was attempted.  It is important 
that the monoclonal antibody can detect the difference between normal 
prothrombin and PIVKA-II molecule to develop the high sensitivity and 
specificity diagnostic reagent.  The germinal center-associated nuclear 
protein (GANP) transgenic mouse has an advantage in preparation of 
monoclonal antibodies against various epitopes, for which conventional 
mice hardly generate high-affinity monoclonal antibodies by the standard 
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procedures [36].  Yoshimura et al. successfully developed the 
high-affinity monoclonal antibody against PIVKA-II, which is named 3C10, 
using the GANP transgenic mice [37].  Then, a fully automated 
quantitative immunoassay for PIVKA-II was established. 
In the chapter II, the following studies are presented to characterize the 
epitope of 3C10 and evaluate the reactivity to PIVKA-II of the developed 
assay: (1) to identify the 3C10 epitope, (2) to evaluate the dilution linearity 
and correlation with existing assay using MU-3 antibody, (3) to evaluate 
and compare the tube type equivalency with existing assay using MU-3 
antibody [38]. 
In the chapter III, the development of the immunoassay for quantitative 
determination of PIVKA-II with ARCHITECT® analyzer is presented [39].  
Currently, some existing PIVKA-II assays need the manual pretreatment 
step and cannot measure plasma samples.  The developed assay is an 
automated immunoassay and has a high sensitivity against PIVKA-II in 
serum and plasma.  I demonstrated its precision, sensitivity, linearity, high 
dose hook effect, tube type equivalency including serum and plasma tubes, 
assay interferences of potential interfering materials, and correlation with 
the existing assay using MU-3 antibody. 
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Figure 1. The production of normal prothrombin and PIVKA-II in hepatic 
cells 
  
Prothrombin precursor Normal prothrombin
Glu Gla
NAD(P)H + H+ NAD(P)+       CO2, O2        H2O
Vitamin K Vitamin K Vitamin K-H2 Vitamin KO
γ-glutamyl carboxylase PIVKA-II
dithiol-S2 dithiol-(SH)2
dithiol-(SH)2 dithiol-S2
Vitamin K
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Chapter II: 
Characterization of an anti-PIVKA-II antibody and evaluation of a 
fully automated chemiluminescent immunoassay for PIVKA-II 
   
 
Summary 
 
PIVKA-II has been used as a tumor marker to aid in the diagnosis of 
HCC.  Yoshimura et al. [37] developed an anti-PIVKA-II monoclonal 
antibody, 3C10.  I established a fully automated quantitative 
immunoassay for PIVKA-II on the ARCHITECT® i-systems using 3C10 
monoclonal antibody.  The aim of this study was to characterize the 
epitope of 3C10 and to evaluate the reactivity to PIVKA-II of this assay. 
The epitope characterization was examined by using prothrombin Gla 
domain polypeptides which are amino acid residues 17–27 that include four 
Gla residues at positions 19, 20, 25 and 26.  The correlation with Picolumi 
PIVKA-II MONO (Eidia, Tokyo, Japan) and tube type equivalency was 
evaluated by using the developed fully automated quantitative 
immunoassay. 
Peptides having Glu at Gla domains strongly reacted to 3C10 but lost 
reactivity when the Glu at positions 19 or 20 was changed to Gla.  The 
results were equivalent with an existing in vitro diagnostics product for 
PIVKA-II using the MU-3 antibody.  A correlation study with the 
Picolumi PIVKA-II MONO gave a correlation coefficient of 0.99 and a 
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regression slope of 0.92.  No difference between a plain serum tube and a 
rapid serum tube including thrombin (RST) was observed on ARCHITECT 
PIVKA-II. 
The results demonstrate that this anti-PIVKA-II antibody detects 
equivalent epitopes with MU-3 and has equivalent reactivity to PIVKA-II 
as MU-3.  Moreover, the ARCHITECT PIVKA-II assay has good 
correlation with the existing PIVKA-II product, and is applicable for use 
with RST. 
  
14 
 
Introduction 
 
Liver cancer is the seventh most common cancer and the second cause of 
death from cancer worldwide.  The incidence rate and mortality rate were 
10.1 and 9.5 per 100,000 persons in 2012, respectively [1]. 
HCC is the major histologic type among primary liver cancers occurring 
worldwide, accounting for 70% to 85% of the total burden [2].  HCC can 
be treated by resection, liver transplantation, or local ablation with 
radiofrequency for patients diagnosed at an early stage [12].  However, 
AFP is the most commonly used tumor marker for HCC, its clinical 
diagnostic accuracy is unsatisfactory due to low sensitivity and specificity 
[13].  Therefore, there is an urgent need for developing better 
HCC-specific biomarkers.  Several serological biomarkers have been 
suggested as other potential biomarkers for early detection of HCC. 
PIVKA-II, also known as DCP, is a useful marker for the diagnosis of HCC, 
and the combined measurement of PIVKA-II and AFP is superior to AFP 
alone [13, 14]. 
Prothrombin, a blood coagulation protein synthesized in the liver, is 
converted to an active form after the 10 Glu in the Gla domain at positions 
6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 are γ-carboxylated to Gla by 
vitamin-K dependent γ-glutamyl carboxylase.  In patients with HCC, 
γ-carboxylation of prothrombin is impaired so that PIVKA-II is formed 
instead of prothrombin [29].  Liebman et al. [16] first reported that the 
serum PIVKA-II concentration was significantly higher in patients with 
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HCC by radioimmunoassay using a polyclonal antibody.  They purified 
PIVKA-II from ascites fluid of patients with HCC and analyzed its Gla 
content [30].  Then, Motohara et al. [31, 32] made the MU-3 monoclonal 
antibody against PIVKA-II and established an assay system with higher 
sensitivity.  Clinical studies have demonstrated that the assay system 
using MU-3 antibody shows high sensitivity and specificity to PIVKA-II in 
patients with HCC [33].  PIVKA-II has been used as an aid for diagnosis 
of HCC in Japan. 
Sugo et al. [34] reported that the reactivity of MU-3 antibody increased 
when the number of Gla was less than five per molecule.  Furthermore, 
Naraki et al. [35] described the epitope of PIVKA-II reacting to MU-3 
antibody.  The epitope of MU-3 antibody was located within the amino 
acid residues 17–27 in the Gla domain.  They reported that MU-3 
antibody reacted to PIVKA-II with less than four Gla and PIVKA-II 
variants preferentially synthesized in HCC patients have less than four Gla 
whereas PIVKA-II variants in benign liver diseases have more than five 
Gla [35].  Yoshimura et al. developed the monoclonal antibody against 
PIVKA-II, 3C10 [37], and I established a fully automated quantitative 
immunoassay for PIVKA-II.  The aim of this study was to characterize the 
epitope of 3C10 and to evaluate the reactivity to PIVKA-II of this assay. 
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Materials and methods 
 
Preparation of 3C10 antibody 
The 3C10 hybridoma cell line was prepared by immunization of mice 
with the synthesized PIVKA-II peptide 13–27 described by Yoshimura et 
al. [37].  Purification of 3C10 antibody was performed by using Protein G 
Sepharose 4 Fast Flow (GE Healthcare Japan, Tokyo, Japan).  Analyses of 
the purified 3C10 antibody were carried out by SDS-PAGE, gel permeation 
chromatography (GPC), and Western blotting. 
 
Preparation of PIVKA-II antigen 
Human prothrombin (Enzyme Research Laboratories, South Bend, IN, 
USA) was dialyzed against 0.1M ammonium acetate solution and 
lyophilized.  After the lyophilization, the prothrombin was heated for 8 
hours at 105 °C for decarboxylation [40].  The decarboxylated 
prothrombin was purified by a 3C10 coated affinity column and a Superdex 
200 column (GE Healthcare Japan, Tokyo, Japan).  Analysis of the 
PIVKA-II antigen was carried out by GPC. 
 
Assay principal of the automated chemiluminescent immunoassay for 
PIVKA-II on ARCHITECT 
The ARCHITECT PIVKA-II assay is a two-step sandwich immunoassay, 
using chemiluminescent paramagnetic microparticle technology for 
quantitative determination of PIVKA-II.  The ARCHITECT PIVKA-II 
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assay utilizes microparticles coated with 3C10 antibody which recognizes 
an epitope in PIVKA-II within the Gla domain at the N-terminus as the 
solid phase to capture PIVKA-II.  The analyte-microparticle complex is 
detected with an acridinium labeled murine anti-prothrombin monoclonal 
antibody MCA 1–8 (Abbott Laboratories, IL, USA) conjugate, which 
recognizes an epitope in prothrombin part of the Gla domain (amino acid 
33–46) shown in Figure 2. 
Following a wash step, pre-trigger and trigger solutions are added to the 
reaction mixture.  The resulting chemiluminescent reaction is measured as 
relative light units (RLUs).  The RLUs detected by the ARCHITECT 
optical system are related to the amount of PIVKA-II Ag in the sample. 
 
Gla domain polypeptide 
Peptides used for epitope characterization were purchased from the 
Toray Research Center (Tokyo, Japan).  The purity of all peptides was 
confirmed to be more than 95% by high performance liquid 
chromatography. 
 
Specimens 
The AFP positive sera for the dilution linearity study of the 
ARCHITECT PIVKA-II were obtained from ProMedDx, LLC (Norton, 
MA, USA).  Serum specimens for the correlation of the ARCHITECT 
PIVKA-II with Picolumi PIVKA-II MONO were obtained from ProMedDx, 
LLC and Bioreclamation IVT (Hicksville, NY, USA).  Normal matched 
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specimens from blood collected in a plain serum tube, a serum separator 
tube (SST) and a RST were obtained from ProMeDx, LLC.  All human 
specimens used for this study were collected under institutional review 
board approved protocols. 
 
Evaluation methods 
The epitope characterization studies of 3C10 and MU-3 antibodies were 
examined with competing peptides against PIVKA-II antigens by the 
ARCHITECT PIVKA-II assay and Picolumi PIVKA-II MONO assay, 
respectively.  The ten kinds of peptides prepared at various concentrations 
were mixed with 480 mAU/mL PIVKA-II, and inhibition by each peptide 
was measured by the ARCHITECT PIVKA-II and Picolumi PIVKA-II 
MONO assays. 
Reactivity of 3C10 to the decarboxylated prothrombin and to native 
PIVKA-II from five individual serum specimens was tested in the dilution 
linearity study of ARCHITECT PIVKA-II assay.  The decarboxylated 
prothrombin and native PIVKA-II adjusted to 30,000 mAU/mL were 
diluted to 30.03%, 9.02%, 2.71%, 0.81%, 0.24%, 0.07%, and 0.02% with 
the ARCHITECT PIVKA-II calibrator diluent and measured by 
ARCHITECT PIVKA-II assay.  The values of coefficient of 
determination (R2) for a linear regression were calculated. 
Correlation of the ARCHITECT PIVKA-II with the Picolumi PIVKA-II 
MONO across the measuring range was evaluated using 119 serum 
specimens from various hepatic diseases including AFP positive patients, 
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liver cancer, non-alcoholic fatty liver disease, liver cirrhosis, hepatitis C, 
etc.  Correlation was analyzed by using the Passing–Bablok regression 
method and the Spearman's correlation coefficient. 
Sample type equivalency was evaluated with specimens drawn from 5 
normal individuals using 3 types of blood collection tubes (plain serum 
tube, SST and RST).  Both neat samples and samples spiked with 100 
mAU/mL of PIVKA-II antigen were assayed by the ARCHITECT 
PIVKA-II and Picolumi PIVKA-II MONO assays.  The PIVKA-II value 
of each sample was compared to the value of the corresponding plain 
serum tube sample.  Statistical differences versus plain serum tube were 
evaluated using the paired t-test. 
Data were analyzed using Analyse-It version 2.22 (Analyse-It Software 
Ltd., Leeds, UK). 
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Results 
 
Characterization of the 3C10 antibody epitope 
To identify the epitope of the 3C10 and MU-3 antibodies, the inhibition 
between PIVKA-II and the competing peptides against PIVKA-II antigens 
was tested by the ARCHITECT PIVKA-II and Picolumi PIVKA-II MONO 
assays.  Ten peptides were used to analyze the epitope of 3C10 and MU-3 
antibody.  The amino acid sequences of the 10 peptides are shown in 
Table 1.  There are four Gla residues (positions 19, 20, 25 and 26) 
between amino acid 17 to 27 in the Gla domain.  I prepared 8 possible 
combinations (peptide-1 to 8) to convert each Gla to Glu in positions 19, 20 
and 25.  Furthermore, I prepared 4 possible combinations (peptide-1, 4, 9 
and 10) to convert each Gla to Glu in positions 25 and 26 with Glu in 
positions 19 and 20. 
The inhibition rates by peptide-1 to 8 on ARCHITECT PIVKA-II assay 
and Picolumi PIVKA-II MONO assay are shown in Figures 3 A and B.  
Peptide-1, where all 4 positions are Glu residues, most strongly inhibited 
the binding of 3C10 and MU-3 to PIVKA-II antigen.  The half maximal 
Inhibitory Concentrations (IC50) to 3C10 and MU-3 by peptide-1 were 
0.84 μM and 0.98 μM, respectively.  Peptide-4, with Gla at position 25, 
showed slightly lower inhibition to 3C10 and MU-3 than peptide-1.  The 
IC50 to 3C10 and MU-3 by peptide-4 were 3.10 μM and 5.75 μM, 
respectively.  Peptide-2 and 3, with Gla at positions 19 and 20, 
respectively, weakly inhibited the reaction to 3C10 and MU-3.  Peptides 5, 
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6, 7, and 8 contain 2 or more Gla residues and did not inhibit the reaction to 
3C10 and MU-3.  The inhibition rates by peptide 1–8 to 3C10 were 
similar with the inhibition to MU-3.  These results showed that at least 
one Glu at positions 19 or 20 is essential for 3C10 antibody binding and the 
further addition Glu at position 25 enhances the 3C10 antibody binding.  
Moreover, the 3C10 binding affinities to the peptides were equivalent to 
the MU-3 binding affinities. 
The inhibition rates by peptide-1, 4, 5, 8, 9 and 10 on ARCHITECT 
PIVKA-II assay and Picolumi PIVKA-II MONO assay are shown in 
Figures 3 C and D.  Peptide-9 strongly inhibited the reaction to 3C10 and 
MU-3.  The inhibition rates were equivalent with peptide-1.  The IC50 to 
3C10 and MU-3 by peptide-9 were 1.10 μM and 1.49 μM, respectively.  
Peptide-10 showed slightly lower inhibition to 3C10 and MU-3 than 
peptide-9.  The inhibition rates were equivalent with peptide-4.  The 
IC50 to 3C10 and MU-3 by peptide-10 were 4.95 μM and 9.23 μM, 
respectively.  These results showed that the further addition Glu at 
position 26 has no effect on the 3C10 antibody binding as well as the MU-3 
antibody binding. 
 
Reactivity of 3C10 antibody to decarboxylated prothrombin and to 
native PIVKA-II in serum specimens 
The dilution linearity study of the ARCHITECT PIVKA-II was 
examined by using decarboxylated prothrombin and native PIVKA-II from 
five individual patients.  The linearity of this assay is shown in Figure 4.  
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The R2 value for a linear regression through the measurement range of 
ARCHITECT PIVKA-II assay of the decarboxylated prothrombin was 
0.985.  The R2 values of native PIVKA-II were from 0.976 to 0.982. 
 
Correlation between the Picolumi PIVKA-II MONO and the 
ARCHITECT PIVKA-II assay 
I evaluated the correlation between the ARCHITECT PIVKA-II assay 
and the Picolumi PIVKA-IIMONO assay (existing PIVKA-II product in 
Japan).  The result is shown in Figure 5.  The regression slope calculated 
using the Passing–Bablok regression method was 0.92.  The Spearman's 
correlation coefficient was 0.99. 
 
Evaluation of tube type equivalency between plain serum tube, SST 
and RST 
I evaluated the value differences by using three types of serum tubes. 
The value differences of the neat samples and samples spiked with 100 
mAU/mL of PIVKA-II antigen between plain serum tube and the two other 
serum tubes on ARCHITECT PIVKA-II and Picolumi PIVKA-II MONO 
assays are shown in Figure 6.  The mean differences of SST and RST 
versus plain serum on ARCHITECT PIVKA-II were 1% and 4%, 
respectively.  The mean differences of SST and RST versus plain serum 
on Picolumi PIVKA-IIMONO were −4% and −16%, respectively.  The 
differences of SST and RST versus plain serum on ARCHITECT 
PIVKA-II and the difference of SST versus plain serum on Picolumi 
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PIVKA-II MONO were non-significant.  However the PIVKA-II level 
using RST on Picolumi PIVKA-II MONO was significantly lower than 
PIVKA-II level using the plain serum tube. 
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Discussion 
 
In this study, I characterized the epitope of 3C10 antibody that was 
developed by immunization with the synthesized peptide 13–27 of 
PIVKA-II.  To identify the epitope in Gla domain of PIVKA-II that is 
detected by 3C10, ten combinations of changes of the four Gla to Glu 
amino acid residues in the Gla domain were evaluated.  The results 
showed that binding to 3C10 was significantly decreased when one or both 
of the Glu at positions 19 and 20 was changed to Gla.  Therefore, the Glu 
at positions 19 or 20 are essential for 3C10 antibody binding.  The 
addition of Glu at position 25 enhanced the 3C10 antibody binding.  The 
further addition of Glu at position 26 is no effect on the 3C10 antibody 
binding.  The inhibition results to 3C10 using ten peptides were 
equivalent with those for MU-3.  The inhibition results to MU-3 were 
similar to the results reported by Naraki et al. [35].  The results indicate 
that the epitope of 3C10 antibody is equivalent to that of the MU-3 
antibody. 
The 3C10 antibody showed equivalent reactivity to decarboxylated 
prothrombin and to native PIVKA-II from the suspected patient with HCC 
through the measurement range of ARCHITECT PIVKA-II assay.  These 
results indicate that the 3C10 antibody binds to native PIVKA-II in the 
patient serum equivalent to a decarboxylated prothrombin.  I evaluated the 
correlation between ARCHITECT PIVKA-II using the 3C10 antibody and 
Picolumi PIVKA-II MONO using the MU-3 antibody by using liver 
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diseases specimens including patients with liver cancer.  The slope and 
correlation coefficient were good.  From these results, the ARCHITECT 
PIVKA-II assay using 3C10 antibody gave similar detection of PIVKA-II 
in clinical specimens to the existing PIVKA-II assays using theMU-3 
antibody.  However, the numbers of tested clinical specimens were 
limited in this study.  A more extensive clinical study of the ARCHITECT 
PIVKA-II assay should be performed in the future. 
In Japan, the PIVKA-II assay has been commonly used as an aid of 
diagnosis and monitoring for the patients with HCC.  However, some 
commercial available PIVKA-II assays have limitations to the usage of 
blood collection tubes.  I performed the tube type study by using three 
kinds of serum tubes on ARCHITECT PIVKA-II and Picolumi 
PIVKA-IIMONO assays.  In these results, no differences between serum 
tube types were observed on the ARCHITECT PIVKA-II assay, whereas 
the PIVKA-II levels collected by RST were significantly decreased on 
Picolumi PIVKA-II MONO assay.  Thrombin cleavages in human 
prothrombin were identified at Arg51-Thr52/Arg54-Asp55, Arg155-Ser156, and 
Arg284-Thr285 [41–43].  Petrovan et al. [44] reported that the rate of 
cleavage at Arg51-Thr52/Arg54-Asp55, Arg155-Ser156, and Arg284-Thr285 is 
greatly affected by the presence of calcium ions.  In the absence of 
calcium ions, thrombin relatively efficiently proteolyzes peptide bonds at 
Arg51-Thr52/Arg54-Asp55 and Arg155-Ser156.  Church et al. [45] reported the 
cleavage of prothrombin by thrombin at Arg155-Ser156 is inhibited in the 
presence of calcium ions, and the protective effect has been attributed to 
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conformational changes mediated by calcium ions binding to the Gla 
domain.  It was reported that the Gla domain in PIVKA-II does not bind 
to calcium ions [46].  Thrombin may cleavages the peptide bonds at 
Arg51-Thr52/Arg54-Asp55 and Arg155-Ser156 on PIVKA-II.  The 
ARCHITECT PIVKA-II uses two different antibodies each which can 
recognize a peptide in the Gla domain.  Therefore, the assay is not 
significantly affected by the PIVKA-II cleavages by proteases.  The 
differences of PIVKA-II levels collected by RST versus serum plain tube 
between ARCHITECT PIVKA-II and Picolumi PIVKA-II MONO might 
be caused by the PIVKA-II cleavage by thrombin. 
In conclusion, the results demonstrate that the anti-PIVKA-II antibody 
3C10 has equivalent epitopes and reactivity to PIVKA-II with MU-3.  
Moreover, the fully automated ARCHITECT PIVKA-II assay using 3C10 
has good correlation with existing PIVKA-II product, and is applicable to a 
rapid serum tube. 
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Figure 2  Assay principal of the ARCHITECT PIVKA-II. 
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Table 1  Amino acid sequences of the Gla domain and peptides used for 
epitope determination.  Gla residues are denoted by γ. 
 
  
Peptide 17 18 19 20 21 22 23 24 25 26 27
Peptide-1 C V E E T C S Y E E A
Peptide-2 C V γ E T C S Y E E A
Peptide-3 C V E γ T C S Y E E A
Peptide-4 C V E E T C S Y γ E A
Peptide-5 C V γ γ T C S Y E E A
Peptide-6 C V E γ T C S Y γ E A
Peptide-7 C V γ E T C S Y γ E A
Peptide-8 C V γ γ T C S Y γ γ A
Peptide-9 C V E E T C S Y E γ A
Peptide-10 C V E E T C S Y γ γ A
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
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C. 
 
D. 
 
Figure 3  Inhibition of 3C10 andMU-3 antibody reactivity to PIVKA-II by 
various peptides with residues at positions 19, 20, 25 and 26 having 
different Gla and Glu.  PIVKA-II was mixed with the peptide 1–8, and the 
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inhibition rate to anti-PIVKA-II antibody by each peptide was measured by 
ARCHITECT PIVKA-II assay (A) and Picolumi PIVKA-IIMONO (B).  
PIVKA-II was mixed with the peptide 1, 4, 5, 8, 9 and 10, and the 
inhibition rate to anti-PIVKA-II antibody by each peptide was measured by 
ARCHITECT PIVKA-II assay (C) and Picolumi PIVKA-IIMONO (D). 
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Figure 4  Reactivity of 3C10 to the decarboxylated prothrombin and to 
native PIVKA-II from five serum specimens by the dilution linearity study 
of ARCHITECT PIVKA-II assay.  The R2 values of patient-1, 2, 3, 4, 5, 
and decarboxylated prothrombin were 0.976, 0.979, 0.979, 0.982, 0.982, 
and 0.985, respectively. 
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Figure 5 Correlation between the Picolumi PIVKA-II MONO and the 
ARCHITECT PIVKA-II assay. 
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Figure 6  Evaluation of tube type equivalency between plain serum tube, 
SST and RST.  The neat samples and spiked samples which were added 
100 mAU/mL of PIVKA-II antigen into each specimen were assayed by the 
ARCHITECT PIVKA-II (A) and Picolumi PIVKA-II MONO (B).  The 
PIVKA-II value of each sample was compared to the value of the 
corresponding plain serum tube sample.  The p-value of the statistical 
differences versus plain serum was calculated by the paired t-test. 
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Chapter III: 
Development and evaluation of analytical performance of a fully 
automated chemiluminescent immunoassay for protein induced by 
vitamin K absence or antagonist II 
 
 
Summary 
 
PIVKA-II, an abnormal form of prothrombin, has been used as an aid in 
the diagnosis of HCC as a tumor marker.  I developed a fully automated 
quantitative immunoassay for PIVKA-II on the ARCHITECT® i systems.  
The aim of this study was to evaluate the analytical performance of this 
assay. 
Assay imprecision, sensitivity, dilution linearity, high dose hook effect, 
sample type equivalency, assay interferences of potential interfering 
materials and correlation with Picolumi PIVKA-II (Eidia, Tokyo, Japan) 
were evaluated. 
The percentage coefficient of variation (%CV) of total imprecision 
ranged from 2.8% to 5.4% with 10 levels of samples. The limit of blank 
(LoB), limit of detection (LoD), and limit of quantitation (LoQ) were less 
than 0.63mAU/mL, 1.62mAU/mL, and 8.25mAU/mL, respectively.  
Linearity up to 30,000mAU/mL, no high dose hook effect, no difference 
among sample types and no interference of common drugs and endogenous 
substances were observed.  Correlation study with the Picolumi PIVKA-II 
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gave a correlation coefficient of 0.93 and a regression slope of 1.07. 
The results demonstrate that the fully automated prototype ARCHITECT 
PIVKA-II assay is an accurate, highly sensitive and precise assay for the 
measurement of PIVKA-II levels in human sera and plasmas. 
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Introduction 
 
Liver cancer is the fifth most common cancer in men and the seventh in 
women but is the third leading cause of cancer death, because of its high 
fatality rate (mortality is 93% of incidence) [1].  About 85% of the burden 
is in developing counties with more than 50% in China alone.  The 
regions with high incidence of liver cancer are West and Central Africa, 
and East and Southeast Asia.  In contrast, incidence rates are generally 
low in developed countries except Japan and Southern Europe [1].  HCC 
is the major histologic type among primary liver cancers occurring 
worldwide, accounting for 70% to 85% of total burden [2]. 
Chronic infection by either HBV or HCV is a major risk factor for HCC. 
Approximately 80% of HCC is estimated to be attributable to HBV or 
HCV worldwide [3].  Carcinogenic risk of HBV carriers is 223-fold that 
of non-carriers [4].  Infection by HCV is the most common predisposing 
factor in some developed countries, including Japan [5]. 
Recently in some historical high risk regions, liver cancer rates 
decreased, possibly due to a reduction in HBV infection by improvement of 
hygiene and sanitation conditions.  In contrast, incident rates are 
increasing in some developed areas, including the United State and Central 
Europe, possibility due to the obesity epidemic and the rise in HCV 
infection through continued transmission by injection drug users [47].  
During the past three decades from 1980 to 2010, the overall age adjusted 
incidence rate of liver cancer in the United State has tripled from 2.63 to 
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8.07 per 100,000 persons [48]. 
One of the reasons for the high fatality rate of HCC is the difficulty of 
detection for HCC in early stage since it is an asymptomatic disease, 
therefore many patients are not treated in the early stages.  Early detection 
of HCC by surveillance in high risk groups is an appropriate way to 
improve the survival rate in patients with HCC [6–11]. 
PIVKA-II, also known as DCP, is an abnormal form of the coagulation 
protein, prothrombin.  PIVKA-II is a functionally defective prothrombin 
resulting from decline of the carboxylation of 10 glutamic acid residues at 
the N-terminus [15]. 
The level of PIVKA-II is elevated in patients with HCC. PIVKA-II level 
is not correlated with the levels of AFP or AFP-L3, which are other 
representative biomarkers for HCC.  Therefore PIVKA-II can be used 
along with AFP or AFP-L3 as a complementary biomarker for HCC.  
Thus, the combination of two markers enhances the sensitivity of diagnosis 
of HCC, but minimizes the decrease in specificity [15–18].  The Japan 
Society of Hepatology recommends measurement of two or more tumor 
markers for the diagnosis of small HCC [19]. 
Many studies showed serum PIVKA-II levels are related to tumor size, 
vascular invasion, intrahepatic metastasis and frequency of recurrence after 
treatment, so PIVKA-II also can be used as a prognostic predictor in 
patients with HCC [20–24].  PIVKA-II may assume a crucial role to 
decide the most effective therapy according to tumor characterization. 
PIVKA-II has been used as an aid for diagnosis of HCC and monitoring 
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of high risk patients (HCV infections, hepatitis/cirrhosis, and HBV 
infections) for development of HCC for more than 20 years in Japan [19]. 
I report here the development and evaluation of the analytical 
performance of a fully automated immunoassay for PIVKA-II on the 
ARCHITECT i systems (Abbott Japan, Tokyo, Japan). 
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Materials and methods 
 
Assay principle 
The ARCHITECT PIVKA-II assay is a two-step immunoassay, using 
chemiluminescent paramagnetic microparticle technology for quantitative 
determination of PIVKA-II.  The analyte, PIVKA-II, is captured by 
paramagnetic microparticles coated with a recombinant murine monoclonal 
anti-PIVKA-II antibody 3C10 (Abbott Laboratories, IL, USA), which 
recognizes an epitope in PIVKA-II within the Gla domain (amino acid 13–
27) at the N-terminus.  The analyte microparticle complex is detected with 
an acridinium labeled murine anti-prothrombin monoclonal antibody MCA 
1–8 (Abbott Laboratories) conjugate, which recognizes an epitope at the 
N-terminus in prothrombin (Figure 7). 
In the first step, 30 μl of sample, 50 μl of assay buffer and 50 μl of anti- 
PIVKA-II antibody coated microparticles are combined and incubated for 
18 min.  After washing, 50 μl of acridinium labeled anti-prothrombin 
antibody conjugate is added and incubated for 4 min.  Following an 
additional wash step, pre-trigger and trigger solutions are added to the 
reaction mixture.  The resulting chemiluminescent reaction is measured as 
RLUs. The RLUs detected by the ARCHITCT optical system is related to 
the amount of PIVKA-II Ag in the sample.  The assay is fully automated 
and an assay result can be obtained within 30 min after initial sample 
aspiration.  The measuring range of this assay was designed from 10 to 
30,000 mAU/mL.  Calibrators were prepared from PIVKA-II antigen 
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diluted in buffer solution containing bovine serum albumin.  The 
calibrator levels are 0, 40, 100, 300, 5000 and 30,000 mAU/mL. 
 
PIVKA-II antigen 
PIVKA-II antigen was prepared from human prothrombin (Enzyme 
Research, IN, USA) by a thermal decarboxylation method described by 
Bajaj et al. [40].  PIVKA-II value of the antigen was determined by 
comparison to the Picolumi PIVKA-II Assay (Eidia, Tokyo, Japan). 
 
Specimens 
AFP positive specimens were obtained from ProMedDx, LLC (MA, 
USA).  Normal specimens from apparently healthy individuals were 
obtained from ProMeDx, LLC, C-C Biotech (CA, USA) and Denka Seiken 
Co., Ltd. (Tokyo, Japan).  All human specimens used for this study were 
collected under institutional review board approved protocols. 
 
Evaluation methods 
Assay imprecision was evaluated according to the Clinical and 
Laboratory Standards Institute (CLSI) guideline EP5-A3 [49].  Three 
levels of buffer based PIVKA-II quality controls, four levels of serum 
based panels and three levels of plasma based panels were assayed in 
replicates of three at two separate times per day for over 20 days using 
three lots of reagents and four instruments including three different 
versions (two i1000SR, one i2000SR and one i2000).  A high plasma 
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panel spiked with PIVKA-II antigen at 75,000 mAU/mL level was tested 
using the 1:10 auto-dilution protocol. 
The LoB, LoD and LoQ were determined according to the CLSI 
guideline EP17-A2 [50].  Four zero-concentration samples and eight low 
concentration PIVKA-II samples (0.625, 1.25, 2.5, 5, 7.5, 9, 10, 15 
mAU/mL) were assayed in replicates of two during five different days 
using three reagent lots and five instruments (two i1000SR and three i2000). 
LoB was set as the 95th percentile of the zero-concentration samples' 
values.  For LoD calculation, normality of the distribution of the lowest 
concentration PIVKA-II sample which 95% replicate showed over LoB 
was confirmed using the Shapiro–Wilk test.  After the confirmation, LoD 
was calculated using the equation: LoD = LoB + (Cβ ∗ SDS), where Cβ = 
1.645 / [1 − 1 / (4 ∗ f)], f = degrees of freedom of SDS, SDS = standard 
deviation (SD) of the low concentration samples.  LoQ was set as the 
lowest concentration that showed a total error of 30% (10% bias + 2 × 10% 
CV).  LoB, LoD and LoQ were calculated from merged data of all reagent 
lots on each instrument. 
Reagent on-board stability studies were performed with three lots of 
reagents using nine instruments.  Three levels of buffer based PIVKA-II 
quality controls, four levels of serum based panels and three levels of 
plasma based panels were assayed in replicates of five at 20 test points 
using reagents stored on-board the instrument during 30 days.  A 
calibration curve was established on the initial day and concentration of 
each sample was determined using the stored calibration curve.  
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Concentrations of the samples were evaluated for trending over time. 
Dilution linearity was assessed according to the CLSI guideline EP06-A 
[51] with two serum and one plasma specimens spiked with PIVKA-II 
antigen.  The specimens were diluted from 100% to 0.01% with the 
ARCHITECT PIVKA-II calibrator diluent across the measuring range.  
Regression analyses of the observed diluted concentrations were compared 
to expected values based on the corresponding concentration of the 
undiluted specimen. 
High dose hook effect was assessed by testing of high level PIVKA-II 
samples beyond the measuring range of the assay.  The high level 
PIVKA-II samples were prepared from pooled serum spiked with 
PIVKA-II antigen to 60,000, 100,000, 200,000, 300,000, 400,000, and 
600,000mAU/mL.  All samples were assayed in replicates of five using 
four instruments (three i2000 and one i1000SR).  Mean RLU of each 
sample was compared with mean RLU of Calibrator-F, the highest level 
calibrator. 
Sample type equivalency was evaluated with specimens drawn from 16 
normal individuals using seven types of blood collection tubes (plain serum 
tube (Terumo, Tokyo, Japan), SST tube (Becton, Dickinson and Company 
(BD), NJ, USA), EDTA K2 tube (Terumo), EDTA Na2 tube (Terumo), 
lithium heparin tube (Terumo), lithium heparin PST tube (BD) and sodium 
heparin tube (Terumo)).  The 20 mAU/mL or 200 mAU/mL of PIVKA-II 
antigen was spiked into each specimen and assayed in replicates of three.  
The mean of the PIVKA-II value of each sample was compared to mean 
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value of the corresponding plain serum tube sample. 
Assay interferences of potential interfering materials including 
endogenous substances, nutritional supplements and therapeutic agents 
were evaluated based on the CLSI guideline EP7-A2 [52].  Each material 
was diluted with appropriate diluents and spiked into the five low level 
serum samples and five high level serum samples prepared by spiking with 
a high titer specimen.  The diluent used for the preparation of the spiked 
materials was spiked into the low level and high level samples in the same 
manner for use as controls.  All samples were assayed in replicates of 
twelve.  The mean of the PIVKA-II value of each test sample was 
compared to mean value of the corresponding control sample. 
Correlation of the prototype ARCHITECT PIVKA-II with Picolumi 
PIVKA-II across the measuring range was evaluated using 81 AFP positive 
sera and 151 normal sera.  Statistical analyses for the correlation were 
performed using Analyse-it version 2.30 (Analyse-it Software, Ltd., Leeds, 
UK). 
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Results 
 
Performance evaluations of the ARCHITECT PIVKA-II assay 
The total imprecision determined with each sample type and instrument 
type is shown in Table 2.  The %CV was between 2.8 and 5.4 over the 
investigated concentration range from 20.28 to 78,800.74 mAU/mL. 
The LoB, LoD and LoQ ranged from0.00 to 0.63, from0.73 to 1.61 and 
from 2.38 to 8.25 mAU/mL, respectively (Table 3). 
The reagent on-board stability results showed no significant change of 
sample concentrations.  The 95% confidence interval of concentration 
shift% from initial day to 30 days was 2.0% to 3.2%. 
The linearity of this assay over the range of 3.85 to 39,991.70 mAU/mL 
using three samples is shown in Figure 8-A.  The Spearman's correlation 
coefficient between expected values and observed values of each sample 
was 1.00.  The recovery of diluted samples ranged from 89% to 105%. 
No high dose hook effect was observed in the testing conditions, up to 
600,000 mAU/mL (Figure 8-B).  Higher concentration samples gave 
higher RLU and no samples showed lower RLU than Calibrator-F RLU 
(30,000 mAU/mL, upper limit of the measuring range). 
The value differences between plain serum and various types of 
specimens are shown in Table 4-a.  The mean percentage differences of 
each specimen type ranged from −0.4% to 3.7%. 
The effects of potential interfering materials are shown in Table 4-b.  
The mean percentage differences between test samples and control samples 
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ranged from -6.4% to 7.2%. 
 
Correlation between the Picolumi PIVKA-II and the ARCHITECT 
PIVKA-II assay 
The correlation between the Picolumi PIVKA-II and the prototype 
ARCHITECT PIVKA-II is shown in Figure 9.  The regression slope 
calculated using the Passing-Bablok regression method was 1.07.  The 
Spearman's correlation coefficient was 0.93. 
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Discussion 
 
In the present study, the analytical performance of ARCHITECT 
PIVKAII assay was evaluated.  The assay demonstrated good precision 
and high sensitivity.  There is variability in LoQ (2.38–8.25 mAU/mL), 
but the highest LoQ was less than 10 mAU/mL against the reported cut-off 
of 40mAU/mL [53].  The good linearity over the measuring range, no 
hook effect up to 600,000 mAU/mL and no interference of common 
therapeutic agents, nutritional supplements and endogenous substances 
were confirmed.  I demonstrated that the ARCHITECT PIVKA-II Assay 
can be used with various types of serum and plasma samples.  The 
correlation data showed the prototype ARCHITECT PIVKA-II gives 
equivalent PIVKA-II values to those of the Picolumi PIVKA-II, the 
regulatory approved PIVKA-II assay in Japan. 
In Japan, PIVKA-II has been commonly employed as a HCC specific 
tumor marker.  The Japan Society of Hepatology recommended the 
measurement of tumor markers combined with ultrasonography at intervals 
of 2–6 months for regular screening in high risk patients with type C 
chronic liver disease, type B chronic liver disease and cirrhosis [19].  
Since PIVKA-II, AFP and AFP-L3 are complementary biomarkers, 
measurement of two or more tumor markers is useful for a precise 
diagnosis of HCC [15-18].  The National Health Insurance in Japan 
covers measurements of AFP, PIVKA-II and AFP-L3.  In contrast, 
outside Japan only ultrasonography and AFP are commonly used for 
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monitoring of the high risk patients and there are no guidelines regarding 
PIVKA-II usage for diagnosis of HCC so far. 
Although prompt determination of the PIVKA-II level is important for 
an appropriate treatment decision, it has not been achieved so far even in 
Japan.  Because the instrument used for the most predominant assay kit 
for PIVKA-II in Japan is not prevalent in clinics and hospitals.  Therefore 
most samples are shipped to and assayed in commercial clinical 
laboratories which take several days to report the assay results after the 
initial sample collection.  Because the second major assay kit, Lumipulse 
PIVKA-II, in Japan can't use plasma samples, collected blood samples 
must be held for more than 30 minutes to allow the serum to clot, it is 
difficult to obtain the assay result before medical treatment for ambulatory 
in a routine medical care process within a day. 
Although human prothrombin is digested to several sub-fragments by 
serine proteases activated in the coagulation cascade [41], the assay can 
detect PIVKA-II in both serum and plasma without the influence of 
degradation of analyte and the interference by the sub-fragments because 
both antibodies used for the ARCHITECT PIVKA-II assay recognize 
epitopes at the N-terminus in PIVKA-II. 
Current assay kits for PIVKA-II on market have some weaknesses. 
Picolumi kit needs manual dilution steps for sample preparation and 
Lumipulse and μTAS Wako DCP can't be used for plasma samples.  The 
ARCHITECT PIVKA-II assay is a convenient fully automated assay which 
has a good analytical performance with high throughput (200 tests / hour) 
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without the pretreatment of specimens.  The ARCHITECT PIVKA-II 
assay was designed to be used with various types of plasma as well as 
serum samples.  Since the incubation time for coagulation is not required 
for plasma samples, the assay results can be obtained earlier than serum 
samples after the sample collection.  These features allow to test and 
obtain the test result before medical treatment in a day when ambulatory 
patients visit. 
This assay provides a convenient automated method for measurement of 
PIVKA-II in both serum and plasma in clinics, hospitals and clinical 
laboratories.  It can support the global use of PIVKA-II for management 
of HCC and the early detection of HCC in high risk groups. 
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Figure 7.  Assay principal of the prototype Architect PIVKA-II assay. 
Capture antibody recognize an epitope in the Gla domain (amino acid (aa) 
13–27), tracer antibody recognize an epitope in the prothrombin part. 
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Table 2  Total assay imprecision (%CV). 
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Table 3  LoB, LoD and LoQ using 5 instruments. 
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Figure 8.  Evaluation of linearity and high dose hook effect. 
A) Relationship between expected PIVKA-II concentrations calculated 
from dilution ratio and neat samples' concentration and observed 
concentrations in three samples (A-1 and A-2: serum samples, A-3: plasma 
sample). 
B) Relationship between PIVKA-II concentrations and relative light units 
(RLUs) on 4 instruments.  Higher concentration gave higher RLU up to 
600,000 mAU/mL. 
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Table 4  Evaluation of sample type equivalence and potential interfering 
materials including endogenous substances, nutritional supplements and 
therapeutic agents. 
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Figure 9.  Correlation between the Japan-approved PIVKA-II assay kit, 
Picolumi PIVKA-II, and the Architect PIVKA-II assay. 
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Chapter IV: 
Conclusion Remarks 
 
 
I characterized the epitope of 3C10 antibody that was developed by 
immunization with the synthesized peptide 13–27 of PIVKA-II.  The 
results showed that the Glu at positions 19 or 20 are essential for 3C10 
antibody binding.  The addition of Glu at position 25 enhanced the 3C10 
antibody binding.  The results indicate that the epitope of 3C10 antibody 
is equivalent to that of the MU-3 antibody.  Also, the results of the 
linearity and correlation with the existing assay using MU-3 antibody 
indicate that the 3C10 antibody binds to native PIVKA-II in the patient 
serum equivalent with MU-3 antibody. 
Some commercial available PIVKA-II assays have limitations to the 
usage of blood collection tubes.  Although human prothrombin is digested 
to several sub-fragments by serine proteases activated in the coagulation 
cascade [39], the ARCHITECT PIVKA-II assay can detect PIVKA-II 
without the influence of degradation of analyte and the interference by the 
sub-fragments because the assay is designed using two different antibodies 
each which can recognize a peptide in the Gla domain.  Therefore, the 
limitations for tube types were improved. 
The fully automated ARCHITECT PIVKA-II assay demonstrated good 
precision and high sensitivity.  The good linearity over the measuring 
range, no hook effect up to 600,000 mAU/mL and no interference of 
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common therapeutic agents, nutritional supplements and endogenous 
substances were confirmed.  I demonstrated that the ARCHITECT 
PIVKA-II Assay can be used with various types of serum and plasma 
samples.  The correlation data showed the prototype ARCHITECT 
PIVKA-II gives equivalent PIVKA-II values to those of the existing 
PIVKA-II assay in Japan. 
In Japan, PIVKA-II has been commonly employed as a HCC specific 
tumor marker.  The Japan Society of Hepatology recommended the 
measurement of tumor markers including PIVKA-II combined with 
ultrasonography at intervals of 2–6 months for regular screening in high 
risk patients with type C chronic liver disease, type B chronic liver disease 
and cirrhosis [19].  The National Health Insurance in Japan covers 
measurements of AFP, PIVKA-II and AFP-L3.  In contrast, outside Japan 
only ultrasonography and AFP are commonly used for monitoring of the 
high risk patients and there are no guidelines regarding PIVKA-II usage for 
diagnosis of HCC so far. 
Current assay kits for PIVKA-II on market have some weaknesses.  
The some existing assays need manual dilution steps for sample 
preparation and some assays have a limitation of measurement for plasma 
samples.  The ARCHITECT PIVKA-II assay is a convenient fully 
automated assay which has a good analytical performance with high 
throughput (200 tests / hour) without the pretreatment of specimens.  The 
ARCHITECT PIVKA-II assay was designed to be used with various types 
of plasma as well as serum samples.  These features allow to test and 
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obtain the test result before medical treatment in a day when ambulatory 
patients visit. 
This assay provides a convenient automated method for measurement of 
PIVKA-II in both serum and plasma in clinics, hospitals and clinical 
laboratories.  The ARCHITECT PIVKA-II has been launched worldwide 
including Japan in 2015.  The assay has been used as an aid in the 
diagnosis of HCC and in monitoring of high risk patients for development 
of HCC.  It can support the global use of PIVKA-II for management of 
HCC and the early detection of HCC in high risk groups. 
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